Alto Neuroscience Secures $120M for Depression Drug Trials

By: crypto insight|2026/03/17 00:00:00

Key Takeaways:

Alto Neuroscience has raised $120 million to advance the development of ALTO-207, targeting treatment-resistant depression.
ALTO-207 combines pramipexole and ondansetron to enhance antidepressant effects for non-responsive patients.
The funding will support Phase 2b and Phase 3 clinical trials and potentially a New Drug Application (NDA) submission.
In 2025, Alto reported a net loss of $63 million but plans significant clinical milestones through 2028.
Alto’s stock experienced a 7% increase in premarket trading following the funding announcement.

WEEX Crypto News, 2026-03-16 15:34:09

Advancing Depression Treatment: ALTO-207 Overview

Alto Neuroscience, a leader in neuropsychiatric disorder treatments, has achieved a significant milestone by securing $120 million to further develop ALTO-207, a promising therapy for treatment-resistant depression. This therapy strategically combines pramipexole, a dopamine receptor agonist, with ondansetron to amplify antidepressant outcomes. The targeted approach aims to reach patients who have not found relief with standard therapies. This funding underpins Phase 2b and 3 trials and an eventual submission for New Drug Application to the FDA.

Financial Backing and Strategic Investors

This capital infusion, primarily led by Commodore Capital, received notable contributions from Dellora Investments, Driehaus Capital Management, Perceptive Advisors, and other institutional heavyweights. Such robust backing underscores confidence in Alto’s precision neuroscience framework. The company’s financing strategy included common stock and pre-funded warrants, showcasing its commitment to advancing ALTO-207 rapidly.

Clinical Trial Roadmap and Expectations

The goal for Alto Neuroscience is clear: transition ALTO-207 through critical trial phases successfully. With Phase 2b trials scheduled for 2026 and Phase 3 following in 2027, Alto aims to solidify data by 2026 for ALTO-101, addressing cognitive impairments in schizophrenia. This disciplined timeline demonstrates Alto’s dedication to groundbreaking advancements in psychiatry.

Financial Health and Future Prospects

Despite reporting a $63 million loss in 2025, Alto’s financial narrative is geared toward future successes. With $177 million in cash reserves earmarked to support operations well into 2028, Alto has strategically positioned itself for achieving pivotal clinical milestones. Notably, research and administrative expenses surpassed $65 million, reflecting an aggressive investment in innovation.

-- Price

Impact on Alto’s Market Standing

Following the funding announcement, Alto’s stock (NYSE: ANRO) experienced a noteworthy uptick of 7% in premarket trading. This positive market reaction highlights investor optimism in Alto’s drug pipeline’s potential to deliver transformative outcomes. Such momentum is crucial in an industry fueled by investor confidence and therapeutic advancements.

ALTO-207’s Unique Composition

ALTO-207 stands out with its dual-action formula combining pramipexole, targeting dopamine pathways, and ondansetron, typically used to block serotonin, thus offering a multi-faceted approach to depression. This novel combination is designed to tackle complexities in treatment-resistant depression, where traditional therapies often fail.

Regulatory Pathway and NDA Submission

A successful journey through Phase 2b and 3 trials will lead to a New Drug Application (NDA) submission to the US FDA. This step represents a major milestone, potentially positioning ALTO-207 as a breakthrough in treating persistent depression forms. Alto’s strategy exemplifies a commitment to rigorous clinical validation, ensuring safety and efficacy before reaching the mass market.

Future Pipeline Developments

Beyond ALTO-207, Alto expands its horizon with ALTO-101, focusing on cognitive impairment linked to schizophrenia. The anticipated proof-of-concept trial results in early 2026 will be pivotal in assessing ALTO-101’s viability. This expansion underscores Alto’s strategic intent to diversify its therapeutic offerings within neuropsychiatry.

Investor Insight and Funding Dynamics

The high-caliber investors rallying behind Alto signal trust in its vision and scientific acumen. The transaction structure incorporating common stock and warrants aligns investor interests with Alto’s long-term goals. This backing is a testament to the robust value proposition that Alto presents within the biotech investment landscape.

Challenges and Strategic Responses

Navigating clinical development’s intricacies presents inherent challenges, including trial execution and regulatory compliance. Alto’s proactive cash management and phased trial approach embody a resilient strategy, mitigating financial risks while maximizing innovation potential. Such a strategic stance is essential in an industry where adaptability and foresight are key drivers of success.

Long-term Outlook

Alto’s approach in securing substantial funding and lining up a comprehensive clinical strategy reflects a sound understanding of the path to therapeutic breakthroughs. Positioning itself at the forefront of precision psychiatry, Alto Neuroscience demonstrates readiness to tackle complex mental health challenges head-on, promoting trust and expectation among stakeholders and investors alike.

FAQ

What is the current status of ALTO-207’s clinical trials?

As of 2026, ALTO-207 is progressing towards Phase 2b trials in the first half of the year, with plans for Phase 3 in early 2027.

How does ALTO-207 aim to improve depression treatment?

ALTO-207 combines pramipexole, a dopaminergic agent, with ondansetron, enhancing antidepressant effects for individuals who do not respond to conventional treatments.

What financial strategies is Alto using to support its operations?

Alto is leveraging $120 million in new funding, alongside maintaining a $177 million cash reserve to fund operations well into 2028, supporting multiple clinical milestones.

How did the recent funding impact Alto’s stock performance?

Following the announcement of securing $120 million, Alto’s stock observed a 7% increase in premarket trading, reflecting investor confidence and positive market sentiment.

What are Alto’s future plans beyond ALTO-207?

Apart from advancing ALTO-207, Alto is also expecting significant developments from ALTO-101, targeting cognitive impairment associated with schizophrenia, with upcoming trial results anticipated in 2026.

On March 16, 2026, in Dallas, Texas, USA, CanGu Company (New York Stock Exchange code: CANG, hereinafter referred to as "CanGu" or the "Company") today announced its unaudited financial performance for the fourth quarter and full year ended December 31, 2025. As a btc-42">bitcoin mining enterprise relying on a globally operated layout and dedicated to building an integrated energy and AI computing power platform, CanGu is actively advancing its business transformation and infrastructure development.

2025 Full Year and Fourth Quarter Financial and Operational Highlights

• Financial Performance:

Total revenue for the full year 2025 was $688.1 million, with $179.5 million in the fourth quarter.

Bitcoin mining business revenue for the full year was $675.5 million, with $172.4 million in the fourth quarter.

Full-year adjusted EBITDA was $24.5 million, while the fourth quarter was -$156.3 million.

• Mining Operations and Costs:

A total of 6,594.6 bitcoins were mined throughout the year, averaging 18.07 bitcoins per day; of which 1,718.3 bitcoins were mined in the fourth quarter, averaging 18.68 bitcoins per day.

The average mining cost for the full year (excluding miner depreciation) was $79,707 per bitcoin, and for the fourth quarter, it was $84,552;

The all-in sustaining costs were $97,272 and $106,251 per bitcoin, respectively.

As of the end of December 2025, the company has cumulatively produced 7,528.4 bitcoins since entering the bitcoin mining business.

• Strategic Progress:

The company has completed the termination of the American Depositary Receipt (ADR) program and transitioned to a direct listing on the NYSE to enhance information transparency and align with its strategic direction, with a long-term goal of expanding its investor base.

CEO Paul Yu stated: "2025 marked the company's first full year as a bitcoin mining enterprise, characterized by rapid execution and structural reshaping. We completed a comprehensive adjustment of our asset system and established a globally distributed mining network. Additionally, the company introduced a new management team, further strengthening our capabilities and competitive advantage in the digital asset and energy infrastructure space. The completion of the NYSE direct listing and USD pricing also signifies our transformation into a global AI infrastructure company."

"As we enter 2026, the company will continue to optimize its balance sheet structure and enhance operational efficiency and cost resilience through adjustments to the miner portfolio. At the same time, we are advancing our strategic transformation into an AI infrastructure provider. Leveraging EcoHash, we will utilize our capabilities in scalable computing power and energy networks to provide cost-effective AI inference solutions. The relevant site transformations and product development are progressing simultaneously, and the company is well-positioned to sustain its execution in the new phase."

The company's Chief Financial Officer, Michael Zhang, stated: "By 2025, the company is expected to achieve significant revenue growth through its scaled mining operations. Despite recording a net loss of $452.8 million from ongoing operations, mainly due to one-time transformation costs and market-driven fair value adjustments, the company, from a financial perspective, will reduce its leverage, optimize its Bitcoin reserve strategy and liquidity management, introduce new capital to strengthen its financial position, and seize investment opportunities in high-potential areas such as AI infrastructure while navigating market volatility."

Fourth Quarter 2025 Ongoing Operations Financial Performance

Revenue

The total revenue for the fourth quarter was $1.795 billion. Of this, the Bitcoin mining business contributed $1.724 billion in revenue, generating 1,718.3 Bitcoins during the quarter. Revenue from the international automobile trading business was $4.8 million.

Operating Costs and Expenses

The total operating costs and expenses for the fourth quarter amounted to $4.56 billion, primarily attributed to expenses related to the Bitcoin mining business, as well as impairment of mining machines and fair value losses on Bitcoin collateral receivables.

This includes:

· Cost of Revenue (excluding depreciation): $1.553 billion

· Cost of Revenue (depreciation): $38.1 million

· Operating Expenses: $9.9 million (including related-party expenses of $1.1 million)

· Mining Machine Impairment Loss: $81.4 million

· Fair Value Loss on Bitcoin Collateral Receivables: $171.4 million

Profit Situation

The operating loss for the fourth quarter was $276.6 million, a significant increase from a loss of $0.7 million in the same period of 2024, primarily due to the downward trend in Bitcoin prices.

The net loss from ongoing operations was $285 million, compared to a net profit of $2.4 million in the same period last year.

The adjusted EBITDA was -$156.3 million, compared to $2.4 million in the same period last year.

Full Year 2025 Ongoing Operations Financial Performance

Revenue

The total revenue for the full year was $6.881 billion. Of this, the revenue from the Bitcoin mining business was $6.755 billion, with a total output of 6,594.6 Bitcoins for the year. Revenue from the international automobile trading business was $9.8 million.

Operating Costs and Expenses

The total annual operating costs and expenses amount to $1.1 billion.

Specifically, they include:

· Revenue Cost (excluding depreciation): $543.3 million

· Revenue Cost (depreciation): $116.6 million

· Operating Expenses: $28.9 million (including related-party expenses of $1.1 million)

· Miner Impairment Loss: $338.3 million

· Bitcoin Collateral Receivable Fair Value Change Loss: $96.5 million

Profitability

The full-year operating loss is $437.1 million. The continuing operations net loss is $452.8 million, while in 2024, there was a net profit of $4.8 million.

The 2025 non-GAAP adjusted net profit is $24.5 million (compared to $5.7 million in 2024). This measure does not include share-based compensation expenses; refer to "Use of Non-GAAP Financial Measures" for details.

Financial Position

As of December 31, 2025, the company's key assets and liabilities are as follows:

· Cash and Cash Equivalents: $41.2 million

· Bitcoin Collateral Receivable (Non-current, related party): $663.0 million

· Miner Net Value: $248.7 million

· Long-Term Debt (related party): $557.6 million

In February 2026, the company sold 4,451 bitcoins and repaid a portion of related-party long-term debt to reduce financial leverage and optimize the asset-liability structure.

Stock Repurchase

As per the stock repurchase plan disclosed on March 13, 2025, as of December 31, 2025, the company had repurchased a total of 890,155 shares of Class A common stock for approximately $1.2 million.

The US AI Startup Is Loving China's Open Source Model

80% of US AI Startups Are Using Chinese Open Source Models

Three Weeks of the US-Iran War: Who's Making Money, Who's Paying the Bill?

Global Losing 10 Million Barrels of Oil Each Day, Russia Earns Over $800 Million in Just Over Two Weeks

Interpreting Polymarket's Major Update Last Night: Fee Expansion, Self-Regulation, and New Incentives

Although there is no information about a token airdrop, the overall community sentiment is optimistic. The real good news is to rhythmically control the positive promotion.

From Human Application to Intelligent Collaboration: How GOAT Network Builds the Next Generation Digital Economy

Embracing the Era of Super Individuals: GOAT Network launches Bitcoin-secured Layer 2 exclusive infrastructure, fully empowering AI entities to usher in a new era of fully automated digital economy.

CZ Washington Dialogue: Crypto Entrepreneurs are Accelerating Their Return to the United States

CZ connects with the DC Blockchain Summit: The prison memoir is about to be published, harshly criticizing the inaccuracies of traditional media reports, and pointing out that if the U.S. wants to become the "global crypto capital," it urgently needs to introduce more sufficient market competition t...